Galderma Standardizes on Medidata Rave for Global Dermatology Trials

Article

Company News Release

Medidata Solutions

today announced that

Galderma

has standardized on the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) platform.
 
Based in Lausanne, Switzerland with a presence in 65 countries, Galderma operates one of the world’s largest R&D facilities dedicated exclusively to developing treatments for dermatological conditions. These state-of-the-art laboratories, located in Sophia Antipolis, France, are complemented by development centers in Princeton, New Jersey and Tokyo, Japan. With an ongoing need to conduct an expanding number of global clinical trials, Galderma’s data management team conducted an extensive, six-month evaluation of three vendors before selecting Medidata Solutions.
 
“Medidata’s track record executing global trials across all trial phases, coupled with their professionalism, proactivity and responsiveness, was critical to our rollout of the Rave solution,” said Francis Gon, head of Global Data Management at Galderma. “Medidata’s training and eLearning tools also made it easy for us to take the solution in-house and begin to independently build and execute studies in any phase and in multiple languages.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.